Cipla Limited (BOM:500087)
1,353.85
-1.95 (-0.14%)
At close: Jun 19, 2026
Cipla Employees
Cipla had 31,369 employees as of March 31, 2026. The number of employees increased by 1,056 or 3.48% compared to the previous year.
Employees
31,369
Change (1Y)
1,056
Growth (1Y)
3.48%
Revenue / Employee
8.87M INR
Profits / Employee
1.24M INR
Market Cap
1.14T
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 31,369 | 1,056 | 3.48% |
| Mar 31, 2025 | 30,313 | 2,549 | 9.18% |
| Mar 31, 2024 | 27,764 | -4,559 | -14.10% |
| Mar 31, 2023 | 32,323 | 6,396 | 24.67% |
| Mar 31, 2022 | 25,927 | 255 | 0.99% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Dr. Reddy's Laboratories | 27,527 |
| Lupin | 24,006 |
| Torrent Pharmaceuticals | 18,258 |
| J. B. Chemicals & Pharmaceuticals | 5,602 |
| Jubilant Pharmova | 5,547 |
| Granules India | 4,066 |
| Caplin Point Laboratories | 3,966 |
| Abbott India | 3,659 |
Cipla News
- 18 hours ago - Pharma sector stocks trade mixed on June 22: Cipla up 2.23%, Indoco Remedies gains 2.38%, Wockhardt falls 1.41% - Business Upturn
- 18 hours ago - Pharma sector stocks today on June 22: Cipla up 2.23%, Indoco Remedies gains 2.38%, Wockhardt falls 1.41% - Business Upturn
- 4 days ago - Cipla advertises Reactin Plus, FDA says recall stock in state - The Times of India
- 5 days ago - Pharma sector stocks today, June 17: Aurobindo Pharma gains 2.26%, Panacea Biotech falls 1.80%, Cipla down 0.32% - Business Upturn
- 6 days ago - Cipla appoints Shivam Puri as CEO of One India Business effective 1st July 2026 - Business Upturn
- 11 days ago - Cipla's Goa facility receives VAI classification from USFDA - Business Upturn
- 13 days ago - Cipla corrects e-voting end date for 90th AGM to 24th June 2026 - Business Upturn
- 13 days ago - Pharma stocks in focus: Nomura highlights strong Zydus growth, Lupin and Cipla see sales decline in April - Business Upturn